Krystal Biotech Inc. has announced a conference call scheduled for July 24, 2025, at 4:30pm ET to discuss the results of the PEARL-2 study, the KB304 clinical development program, and Jeune's pipeline product candidates. The call will also cover the strategic vision for Jeune, a wholly owned subsidiary of Krystal Biotech. The discussion will highlight the positive safety and efficacy results from the Phase 1 study of KB304 for moderate to severe wrinkles of the décolleté. Investors and the general public can access the live webcast at https://www.webcaster4.com/Webcast/Page/3018/52758, and a replay will be available on the Krystal website for those unable to attend the live session.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。